Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatrogon vs Genotropin Treatment Burden in Pediatric GHD
NCT03831880Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2019
- Primary completion
- Aug 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of somatrogon in growth hormone deficiency (GHD) (2 arms), sponsored by Pfizer. Primary endpoint: Total Score Related to Overall Life Interference Assessed at Baseline, Week 12, Week 24. Started Feb 2019; status: completed.
02
Drugs
somatrogon
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT03831880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03831880.